Tempus AI (NASDAQ:TEM) Upgraded to Hold at Freedom Capital

Freedom Capital upgraded shares of Tempus AI (NASDAQ:TEM) to a hold rating in a research note published on Tuesday morning,Zacks.com reports.

A number of other equities analysts have also recently commented on TEM. Needham & Company LLC reissued a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research note on Monday, June 1st. TD Cowen upped their target price on shares of Tempus AI from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Guggenheim lowered their price target on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a report on Monday, March 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tempus AI in a research report on Wednesday, June 17th. Finally, Jefferies Financial Group began coverage on Tempus AI in a research note on Monday, April 13th. They set an “underperform” rating and a $35.00 price objective on the stock. Nine investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Tempus AI has a consensus rating of “Hold” and an average target price of $68.54.

Tempus AI Stock Up 6.3%

Shares of TEM opened at $61.60 on Tuesday. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. The stock has a market capitalization of $11.06 billion, a price-to-earnings ratio of -35.81 and a beta of 3.45. Tempus AI has a 1 year low of $41.73 and a 1 year high of $104.32. The business’s 50 day simple moving average is $50.28 and its 200-day simple moving average is $54.60.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The firm had revenue of $348.12 million during the quarter, compared to analyst estimates of $345.44 million. During the same period last year, the firm posted ($0.24) earnings per share. Tempus AI’s revenue for the quarter was up 36.1% compared to the same quarter last year. As a group, equities analysts expect that Tempus AI will post -1.35 earnings per share for the current fiscal year.

Insider Buying and Selling at Tempus AI

In related news, CEO Eric P. Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $46.70, for a total transaction of $7,763,875.00. Following the completion of the transaction, the chief executive officer directly owned 8,808,533 shares of the company’s stock, valued at approximately $411,358,491.10. The trade was a 1.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 13,550 shares of the company’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $597,148.50. Following the transaction, the chief executive officer owned 603,558 shares in the company, valued at $26,598,801.06. The trade was a 2.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 572,759 shares of company stock valued at $29,238,424. Insiders own 24.26% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

Institutional investors and hedge funds have recently modified their holdings of the business. Aberdeen Group plc lifted its position in shares of Tempus AI by 64.2% during the fourth quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock worth $15,530,000 after purchasing an additional 102,878 shares during the last quarter. Pictet Asset Management Holding SA boosted its stake in shares of Tempus AI by 291.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock valued at $2,948,000 after purchasing an additional 36,096 shares during the period. Bogart Wealth LLC grew its holdings in shares of Tempus AI by 365,087.5% in the fourth quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock worth $3,450,000 after purchasing an additional 58,414 shares during the last quarter. Bamco Inc. NY grew its holdings in shares of Tempus AI by 53.7% in the third quarter. Bamco Inc. NY now owns 263,250 shares of the company’s stock worth $21,247,000 after purchasing an additional 92,007 shares during the last quarter. Finally, Landscape Capital Management L.L.C. increased its stake in Tempus AI by 19.8% in the 3rd quarter. Landscape Capital Management L.L.C. now owns 136,372 shares of the company’s stock worth $11,007,000 after buying an additional 22,581 shares during the period. 24.22% of the stock is owned by institutional investors.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Analyst-style coverage argued Tempus AI remains attractive because of diagnostics momentum, AI platform expansion, and recent FDA-related product gains that may broaden future growth. Tempus AI: Buy On Diagnostics Momentum And AI Platform Expansion
• Positive Sentiment: Some market commentary suggested the recent pullback may be creating a buying opportunity for investors who believe in Tempus AI’s long-term growth story. Tempus AI stock faces a make-or-break moment after its recent pullback
• Neutral Sentiment: Konica Minolta completed the sale of Tempus shares it previously received, which may remove a supply overhang but is not an operating update. Konica Minolta Completes Sale of Tempus Shares to Bolster Balance Sheet
• Negative Sentiment: Biovica said it is refocusing its U.S. commercial strategy and terminating its agreement with Tempus AI, which could reduce a partnership-related opportunity. Biovica Refocuses US Commercial Strategy and Terminates Agreement with Tempus AI
• Negative Sentiment: Recent insider selling by the CFO, CEO, and a director may be pressuring sentiment, even though the trades were made under pre-arranged plans. Tempus AI CEO insider sale filing

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.